Background
==========

Neck circumference (NC) was recently associated with various cardiovascular risk factors such as insulin resistance and biochemical components of metabolic syndrome such as fasting glucose, fasting triglycerides, and blood pressure, independent of body mass index (BMI) and waist circumference \[\[[@B1]\]-\[[@B4]\]\]. However, few studies have assessed the relation between NC and early stage atherosclerosis in Chinese adults \[\[[@B5]\]\].

Aortic stiffness is an established marker for early stage atherosclerosis. The recent European Society of Hypertension/European Society of Cardiology guidelines for management of arterial hypertension suggested measurement of pulse wave velocity (PWV) as a tool for assessment of subclinical atherosclerosis \[\[[@B6]\]\]. PWV is a gold standard for assessing arterial stiffness, and has been widely used as an indicator for early-staged atherosclerosis \[\[[@B7]\]-\[[@B10]\]\]. PWV measured at different sites may reflect the atherosclerotic alterations at central (e.g. carotid femoral pulse wave velocity (cfPWV)) or peripheral arteries (e.g. carotid artery dorsalis pedis pulse wave velocity (cdPWV) and carotid radial pulse wave velocity (crPWV)). cfPWV is recognized as the "gold standard" parameter for the evaluation of arterial stiffness and has had a wide biomedical application \[\[[@B11]\],\[[@B12]\]\]. The analysis of the peripheral pulse wave (cdPWV and crPWV) can provide parameters with different meanings in the arterial dynamics, some already used to assess the arterial stiffness \[\[[@B13]\],\[[@B14]\]\].

The present study aimed to comprehensively investigate the relationship between NC and PWV measures for peripheral and central arterial stiffness in a large Chinese population.

Methods
=======

Study population
----------------

In the cardiometabolic risk in Chinese (CRC) study, we performed a community-based health examination survey for 6,431 individuals (18-93y) who were randomly selected from residents living in the urban area of Xuzhou, China, in 2009. The details of this study have been presented elsewhere \[\[[@B3]\],\[[@B15]\]-\[[@B18]\]\]. All subjects underwent a complete medical examination, a clinical consultation, and blood laboratory tests. All individuals provided details of their demographic, medical history, and use of medication at the time of their clinical consultation. We excluded people who did not undergo PWV determination or omitted blood sampling, and subjects with goiter and other neck masses and deformity. In total, 2,318 subjects were included in the final analyses. There was no significant difference in the clinical characteristics between the participants of the present analysis and those who were not included. The protocol and informed consent document were approved by the ethics committee of the Central Hospital of Xuzhou. All patients gave written informed consent.

Anthropometric measures
-----------------------

Neck Circumference (cm) was measured with head erect and eyes facing forward, horizontally at the upper margin of the laryngeal prominence with a flexible tape. Body weight was measured in light clothing to the nearest 0.1 kg and height to the nearest 0.5 cm. Height and body weight were measured with participants standing without shoes and heavy outer garments. Waist circumference was measured at the minimum abdominal girth to the nearest 0.1 cm. BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Blood pressure (BP) was measured after the subject had rested for at least 5 minutes with a mercury manometer by doctors. Three measurements, 60 seconds apart, were taken. The mean of the three measurements was used for analysis. Hypertension was defined as SBP ≥ 140 mmHg and DBP ≥ 90 mmHg, or the use of antihypertensive medication, according to the seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7).

Assessment of biomarkers
------------------------

Venous blood sample was drawn from all subjects after an overnight fast (10 h). The blood was transferred into glass tubes and allowed to clot at room temperature. Immediately following clotting serum was separated by centrifugation for 15 min at 3,000 rpm. Blood samples were drawn at 120 minutes after the glucose or carbohydrate load. Plasma glucose was measured using the hexokinase glucose-6-phosphate dehydrogenase method (Type 7600; Hitachi Ltd, Tokyo, Japan). The levels of total cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C) were determined enzymatically using an autoanalyzer (Type 7600; Hitachi Ltd., Tokyo, Japan). Fasting insulin was measured by a radioimmunoassay ethod (Pharmacia, Uppsala, Sweden). HbA1c was measured using high performance liquid chromatography(HPLC; HLC-723G7 hemoglobin HPLC ana-lyzer, Tosoh Corp.) according to the standardized method. The 1999 World Health Organization diagnostic criteria were used to diagnose diabetes. Individuals diagnosed by a physician and on antidiabetic medications (self-reported) and/or those who had fasting glucose ≥ 126 mg/dl (≥7 mmol/L) and/or 2-hr post-glucose value ≥ 199.8 mg/dl (≥11.1 mmol/L). National Cholesterol Education Programme (NCEP) guidelines were used for definition of dyslipidemia as follows \[\[[@B19]\]\]: Hypercholesterolemia: serum cholesterol levels ≥ 200 mg/dl (≥5.2 mmol/l). Hypertriglyceridemia: serum TG levels ≥ 150 mg/dl (≥1.7 mmol/l). Low HDL cholesterol: HDL cholesterol levels \<40 mg/dl(\<1.04 mmol/l) for men and \<50 mg/dl (\<1.3 mmol/l) for women. High LDL cholesterol: LDL cholesterol levels ≥ 130 mg/dl(≥3.4 mmol/l).

Assessment of PWVs
------------------

Before the study started, sonographers were trained for PWV measurements. All measurements were performed in a quiet room with controlled ambient temperature. The cfPWV was measured in the supine position after 5 min of bed rest using an automatic waveform analyzer (Complior System, Artech-Medical corp. French), the pulse wave of the carotid and femoral arteries was analyzed, estimating the delay with respect to the ECG wave and calculating the PWV. cdPWV and crPWV were obtained in a similar way, with the pulse wave being measured simultaneously in the right radial, dorsum of foot and right carotid arteries. 16 consecutive electrocardiogram gated waveforms were obtained and removed the three maximum and three minimum. We averaged 10 waveforms. PWV was based on the distance/time ratio (meters/second), was calculated as the path length divided by the transit time and expressed as m/s \[\[[@B13]\]\]. The operators' concordance in pulse wave measurements ranged from 0.85 to 0.92.

Statistical analyses
--------------------

The relations between NC levels (in quintiles) and PWVs were examined using general linear regression models, adjusting for covariates including age, sex, BMI, heart rate(HR), fasting glucose, lipid profiles and BP. The interactions between NC and other cardiometabolic risk factors were assessed by introduction of cross-product term in the regression models. All the reported P values are two tailed. Variables with P values of \< 0.05 were considered statistically significant. Data management and statistical analysis were conducted using SAS statistical software (version 9.1; SAS Institute, Inc., Cary, NC, USA).

Results
=======

The study population was represented by 65.3% of men, with average age of 46.5 years. Table [1](#T1){ref-type="table"} shows the characteristics of the study participants according to NC levels (in quintiles). BMI, waist circumference, BP, and plasma levels of glucose, TC, TG and LDL-C showed significant differences across NC groups.

###### 

Characteristics of participants by NC in quintiles

  **Variables**                    **NC (in quintiles)**                                                               
  -------------------------------- ----------------------- -------------- -------------- -------------- -------------- ----------
  N                                670                     393            381            494            380             
  Age, years                       46.4 ± 10.1             43.6 ± 9.1     45.8 ± 9.5     46.9 ± 9.4     46.8 ± 8.8     0.498
  BMI, kg/m^2^                     22.5 ± 2.4              24.0 ± 2.2     25.0 ± 2.2     26.1 ± 2.3     27.9 ± 3.0     \<0.0001
  WC, cm                           80.4 ± 7.7              84.6 ± 7.1     87.6 ± 7.7     91.7 ± 7.2     96.1 ± 9.0     \<0.0001
  Systolic blood pressure, mmHg    121.1 ± 15.2            124.4 ± 15.2   124.2 ± 15.8   128.3 ± 16.3   130.7 ± 15.6   \<0.0001
  Diastolic blood pressure, mmHg   77.1 ± 11.1             77.9 ± 10.7    80.0 ± 11.4    82.6 ± 11.6    83.9 ± 11.4    \<0.0001
  Fasting glucose, mmol/L          5.2 ± 1.5               5.1 ± 0.9      5.3 ± 1.1      5.3 ± 1.1      5.5 ± 1.4      0.001
  Totalcholesterol, mmol/l         4.9 ± 0.9               5.1 ± 0.9      5.1 ± 0.9      5.1 ± 0.9      5.2 ± 1.0      0.0001
  Triglyceride, mmol/L             1.4 ± 1.2               1.8 ± 1.9      1.8 ± 1.5      2.1 ± 1.7      2.3 ± 2.6      \<0.0001
  LDL-C, mmol/L                    2.9 ± 0.8               3.0 ± 0.8      3.0 ± 0.8      3.1 ± 0.8      3.1 ± 0.8      \<0.0001
  HDL-C, mmol/L                    1.3 ± 0.3               1.3 ± 0.3      1.2 ± 0.3      1.1 ± 0.3      1.1 ± 0.3      0.0037
  Hypertention                     19.7%                   20.1%          22.8%          27.7%          31.8%          \<0.0001
  Diabetes                         6.1%                    7.6%           10.0%          10.9%          12.6%          0.0062
  High LDL                         11.2%                   12.0%          13.9%          18.6%          18.9%          \<0.0001
  Low HDL                          4.2%                    4.8%           5.5%           5.9%           6.3%           0.0159
  Hypertriglyceridemia             9.9%                    11.2%          12.1%          15.8%          17.9%          \<0.0001
  Hypercholesterolemia             10.9%                   12.7%          13.4%          17.6%          18.8%          0.0317

Abbreviations: *WC* waist circumference, *HDL-C* high density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol. Data are age and sex adjusted; Mean ± standard deviation; Linear regression model was used to test trend for continuous variables.

Table [2](#T2){ref-type="table"} displays the associations between PWVs and NC. After adjustment for age and sex, high levels of NC were significantly associated with an increasing trend of cfPWV, crPWV and cdPWV in a dose-dependent pattern. Further adjustment for lipids, glucose, systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, and BMI did not significantly change the associations.

###### 

Associations of NC with central and peripheral arterial stiffness

          **NC (in quintiles)**                                                           
  ------- ----------------------- ------------- ------------- ------------- ------------- ------------------
          **Q1**                  **Q2**        **Q3**        **Q4**        **Q5**        ***P*for trend**
  cfpwv   10.65(1.84)             10.69(1.75)   10.62(1.83)   10.99(2.00)   11.01(1.78)   0.001
  cfpwv   9.62(1.47)              9.67(1.53)    9.75(1.53)    9.96(1.40)    10.02(1.51)   0.049
  cfpwv   10.44(1.53)             10.41(1.43)   10.55(1.62)   10.67(1.55)   10.61(1.50)   0.038

PWVs are presented as mean (standard deviation), adjusted sex, age, TC, TG, HDL, LDL, glucose, SBP, DBP, HR, BMI.

Then we examined whether cardiometabolic risk factors modified the relation between NC and cfPWVs (Table [3](#T3){ref-type="table"}). Age, sex, BMI, HR, diabetes status, and dyslipidemia did not significantly interact with NC in relation to cfPWV.

###### 

Stratified associations between NC and cfPWV by cardiometabolic risk factors

                         **Q1**         **Q2**         **Q3**         **Q4**         **Q5**         **p for trend**   **p for interaction**
  ---------------------- -------------- -------------- -------------- -------------- -------------- ----------------- -----------------------
  Sex                                                                                                                 
   0                     9.87 ± 1.40    10.07 ± 1.79   9.89 ± 1.25    10.46 ± 1.93   10.38 ± 1.50   0.024             0.387
   1                     10.90 ± 1.89   10.94 ± 1.67   10.91 ± 1.94   11.09 ± 2.00   11.28 ± 1.83   0.003              
  Age                                                                                                                 
   \<40                  9.96 ± 1.28    10.23 ± 1.29   10.26 ± 1.37   10.30 ± 1.33   10.49 ± 1.28   0.009             0.506
   40 to 60              10.45 ± 1.33   10.28 ± 1.33   10.27 ± 1.29   10.72 ± 1.42   10.76 ± 1.49   0.048              
   \>60                  11.59 ± 2.39   11.61 ± 2.15   11.43 ± 2.45   11.83 ± 2.59   11.61 ± 2.14   0.183              
  BMI                                                                                                                 
   \<28                  10.65 ± 1.84   10.69 ± 1.76   10.62 ± 1.84   11.00 ± 2.06   10.85 ± 1.57   0.034             0.230
   \> = 28               10.39 ± 1.86   10.78 ± 1.47   10.74 ± 1.74   10.99 ± 1.73   11.18 ± 1.96   0.211              
  HR                                                                                                                  
   \< = 65               10.36 ± 1.56   10.28 ± 1.46   10.28 ± 1.26   10.70 ± 1.66   10.56 ± 1.35   0.030             0.868
   \>65, \< = 75         10.59 ± 1.83   10.69 ± 1.83   10.50 ± 1.81   11.02 ± 1.90   10.99 ± 1.65   0.008              
   \>75                  11.12 ± 2.11   11.15 ± 1.85   11.13 ± 2.23   11.33 ± 2.40   11.40 ± 2.09   0.202              
  Diabetes                                                                                                            
   No                    10.52 ± 1.70   10.59 ± 1.70   10.44 ± 1.57   10.81 ± 1.75   10.87 ± 1.68   0.131             0.316
   Yes                   12.25 ± 2.63   12.13 ± 1.83   12.31 ± 2.85   12.47 ± 3.05   11.95 ± 2.17   0.282              
  Hypercholesterolemia                                                                                                
   No                    10.42 ± 1.80   10.47 ± 1.60   10.54 ± 1.87   10.80 ± 1.89   10.90 ± 1.74   0.018             0.982
   Yes                   10.83 ± 1.89   10.88 ± 1.87   11.08 ± 1.75   11.16 ± 2.11   11.23 ± 1.82   0.010              
  Hypertriglyceridemia                                                                                                
   No                    10.51 ± 1.82   10.56 ± 1.86   10.70 ± 1.89   10.87 ± 2.04   10.91 ± 1.62   0.013             0.996
   Yes                   10.98 ± 1.87   11.03 ± 1.41   11.08 ± 1.64   11.13 ± 1.95   11.31 ± 1.89   0.017              
  High LDL                                                                                                            
   No                    10.51 ± 1.78   10.58 ± 1.63   10.61 ± 1.96   10.93 ± 1.95   11.00 ± 1.83   0.021             0.890
   Yes                   10.66 ± 2.01   10.83 ± 1.94   11.01 ± 1.49   11.06 ± 2.08   11.14 ± 1.70   0.006              
  Low HDL                                                                                                             
   No                    10.70 ± 1.83   10.81 ± 1.89   10.53 ± 1.95   11.03 ± 2.18   10.97 ± 1.86   0.113             0.074
   Yes                   10.47 ± 1.85   10.53 ± 1.34   10.76 ± 1.63   10.95 ± 1.72   11.06 ± 1.70   \<0.001            

Analyses were adjusted for age, sex, BMI, glucose, total cholesterol, triglyceride, HDL-C, LDL-C, blood pressure, heart rate, diabetes, dyslipidemia but not the strata variable. cfPWV is presented as mean ± standard deviation.

We found significant interaction between hypertension status and NC level in relation to cfPWV, adjusted for age, sex, BMI, fasting glucose, lipids and HR (P for interaction = 0.034). The associations between NC and cfPWV were significant (P = 0.02) among the participants with hypertension, but not among those with non-hypertension (Figure [1](#F1){ref-type="fig"}).

![**Interaction between NC and hypertension in relation to cfPWV.** The predicted cfPWV by log-transformed NC in individuals with non-hypertension and hypertension are presented. Analysis was adjusted for age, sex, BMI, fasting glucose, lipids and HR.](s12933-014-0107-x-1){#F1}

Discussion
==========

In this study, we found that high NC was significantly associated increasing PWV measures for both peripheral and central arterial stiffness in Chinese adults. The associations were independent of other adiposity measures such as BMI and waist circumference, as well as traditional cardiometabolic risk factors. Moreover, we found that blood pressure modified the relation between NC and cfPWV.

As a risk factor for cardiovascular disease \[\[[@B20]\]\], aortic stiffness is recognized as an important marker for early artherosclerosis \[\[[@B21]\],\[[@B22]\]\]. cfPWV is considered to be the gold standard method for assessing aortic stiffness \[\[[@B23]\],\[[@B24]\]\], and has been associated with cardiovascular outcomes such as myocardial infarction, heart failure, and mortality \[\[[@B7]\],\[[@B25]\]\]. Individual metabolic syndrome components have been related with subclinical atherosclerosis in previous studies, for example, central obesity showed strong correlation with carotid atherosclerosis \[\[[@B26]\]-\[[@B29]\]\]. Our findings are consistent with several previous studies. Fitch et al. \[\[[@B30]\]\] found significant association between NC and carotid intima thickness. Zhou et al. \[\[[@B31]\]\] found that NC was significantly associated with cardiometabolic risk factors independent of the classical anthropometric indices in adults Chinese.

The precise mechanisms underlying the associations between NC and arterial stiffening remain not fully understood. In our study, adjustment for various cardiometabolic risk factors, such as age, sex, BMI, fasting glucose, lipids, BP and HR, did not change the associations between NC and PWVs, suggesting that the effects of NC are less likely to be mediated by these factors. Various mechanisms have been proposed to link NC with development of atherosclerosis. Upper-body subcutaneous fat has been demonstrated to be responsible for the majority of systemic free fatty acid release, particularly in obese individuals \[\[[@B32]\]\]. It has been shown that elevated concentration of free fatty acid increased oxidative stress \[\[[@B33]\]\] and provoked vascular endothelial injury \[\[[@B34]\]\]. In addition, NC is an important predictor for obstructive sleep apnea (OSA), and OSA has been associated with arterial stiffening \[\[[@B35]\],\[[@B36]\]\].

Intriguingly, we found that the adverse effects of NC on central arterial stiffness appeared to be more evident in people with hypertension than those with normal blood pressure. Notably, on average cfPWV was much higher and its variance was larger in individuals with hypertension than those without hypertension (Figure [1](#F1){ref-type="fig"}); it is therefore not surprising a null association was observed between NC and cfPWV in subjects without hypertension because of the narrow variance. Laakso \[\[[@B37]\]\] reported that a higher NC was associated with about 3-fold increased risk of hypertension after adjustment for BMI. However, our data indicate that the associations between NC and cfPWV were independent of blood pressure, suggesting other mechanisms might be involved to explain the stronger associations in patients with hypertension. High NC has been related to various metabolic changes. We assume that certain changes may interact with hypertension in promoting atherosclerosis. For example, in a previous prospective study, it was found that inflammation-mediated proatherogenic activation led to significant increase of arterial stiffness in essential hypertensive patients \[\[[@B38]\]\]. Our findings suggest that high NC levels may play a more important role in arterial stiffness along with hypertension. This finding might have important clinical implications for prevention and intervention of cardiovascular risk at early stage. Further investigations are warranted to explore the potential mechanisms.

To our knowledge, the present study is among the first to assess the associations of NC and markers of early stage atherosclerosis in apparently healthy Chinese adults. However, several limitations of this study warrant consideration. First, the study is cross-sectional, thus we could not define a causal association between NC and PWVs. Second, neck circumference is used to represent upperbody subcutaneous fat, we did not perform radiographic measures to quantify this depot of fat directly. Potential confounding might exist as risk factors such as cigarette smoking was not measured in our study. Intima-Media Thickness and ankle-brachial-index are complementary parameters to evaluate the severity of early atherosclerosis \[\[[@B39]\],\[[@B40]\]\]. However these markers were not measured in our study. Finally, the study was performed in a Chinese population, further studies in other populations of different ethnicities are warranted to verify our findings.

Conclusions
===========

In summary, we found that high NC was associated with markers of an increased risk of early stage atherosclerosis in Chinese adults, independent of other metabolic risk factors. Blood pressure might modify the associations.
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